Applied TherapeuticsAPLT
APLT
About: Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Employees: 36
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
133% more call options, than puts
Call options by funds: $226K | Put options by funds: $97K
7.75% less ownership
Funds ownership: 98.89% [Q4 2024] → 91.14% (-7.75%) [Q1 2025]
16% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 32
24% less funds holding
Funds holding: 118 [Q4 2024] → 90 (-28) [Q1 2025]
47% less capital invested
Capital invested by funds: $98.5M [Q4 2024] → $51.8M (-$46.7M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
68% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 40
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$1.50
324%
upside
Avg. target
$1.50
324%
upside
High target
$1.50
324%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
RBC Capital Brian Abrahams | 324%upside $1.50 | Sector Perform Reiterated | 14 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
4 weeks ago
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the primary endpoint of 10MWRT at 12 months was not statistically significant (the measure has since been removed from the CMT-FOM clinical outcomes assessment based upon the results of the ACT-CMT study*) Statistically significant improvement in CMT-HI and statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Treatment with govorestat in CMT-SORD-Null rats demonstrated a highly statistically significant 37% (p=0.005) reduction of sorbitol in the sciatic nerve, the tissue of interest, after treatment with govorestat.Reflective of the peripheral neuropathy experienced by patients with CMT-SORD. Govorestat remains generally safe and well tolerated Company remains committed to potential NDA submission of govorestat for treatment of CMT-SORD in 2025 NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare disease, today presented full 12-month clinical results and new topline data from 18 and 24 months from the INSPIRE Phase 2/3 trial of govorestat (AT-007) for the treatment of Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of Charcot-Marie-Tooth (CMT) disease, in an oral presentation at the Peripheral Nerve Society (PNS) 2025 Annual Meeting, being held May 17-20, 2025 in Edinburgh, Scotland.
Neutral
GlobeNewsWire
1 month ago
Applied Therapeutics Reports First Quarter 2025 Financial Results
- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting
Neutral
GlobeNewsWire
1 month ago
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension
Neutral
GlobeNewsWire
1 month ago
NET Power Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 17, 2025 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
GlobeNewsWire
2 months ago
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has filed a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission (“SEC”) related to the Company's Annual Report on Form 10-K for the fiscal year 2024 (the “Form 10-K”). Form 12b-25 will allow the Company an automatic extension of 15 additional calendar days to file the Form 10-K for the fiscal year 2024, which is due on March 31, 2025. The Company is working diligently to finalize its financial statements and currently expects to file its Annual Report on Form 10-K as soon as practicable by April 15, 2025, the end of the 15-day extension period, in accordance with Rule 12b-25.
Neutral
GlobeNewsWire
2 months ago
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
Dr. Baumgartner will advance Applied's preparation for upcoming regulatory interactions Dr. Baumgartner will advance Applied's preparation for upcoming regulatory interactions
Neutral
Accesswire
3 months ago
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. Lawsuit - APLT
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130443&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
3 months ago
Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130340&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
3 months ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Applied Therapeutics, Inc.(APLT) Shareholders
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130271&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
3 months ago
Investors in Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/applied-therapeutics-inc-lawsuit-submission-form?prid=130235&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™